Advent Access is a medical technology startup focused on end-stage renal disease management. A Stanford StartX company and spin-off from A*STAR, Advent’s mission is to pioneer innovations to significantly reduce dialysis cost and restore quality of life for kidney failure patients. The company’s first product is the av-Guardian™ - an award-winning implant technology that aims to improve vascular access reliability, enable less-painful self-cannulation and, in the long run, potentially reduce vascular access related hospitalizations. The av-Guardian™ forms a key component of Advent Access’ dialysis-machine agnostic platform to empower patients to perform hemodialysis independently, safely and more affordably - at home or in novel care environments. The startup is founded with an executive management and investors with a collective experience of pioneering more than ten startups in medtech and a track record of successful IPOs and exits. The company has raised >$5.6M of private investments and research grants to date. For more information, please refer to www.adventaccess.com